19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities

Data ReadoutpositiveBGM0504Positive

AI Analysis

Summary

BrightGene Bio-Medical announced positive clinical data for BGM0504, its GLP-1/GIP dual agonist, demonstrating significant improvements in weight, waist circumference, blood pressure, uric acid, and triglycerides.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

BGM0504 demonstrated 19.3% weight reduction, 16.5 cm waist circumference decrease, 22.9/12.9 mmHg systolic/diastolic blood pressure reductions, 70.7 μmol/L uric acid reduction, and 33.6% triglyceride reduction

Importance:6/10

Sentiment:

0.80

GLP-1/GIPdual agonistweight losscardiometabolicclinical dataChina

Related Companies

$GLUC $MPW $CFOO

Read the original article

Published by PR Newswire Pharma on May 6, 2026 4:10 PM

Read Original